This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Next Generation CAR & T Cell Therapies

REGISTER BY FEBRUARY 10 FOR EARLY EVENT PLATFORM ACCESS

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
February 27 - March 2, 2023 | Part of BPI West
San Diego Convention CenterSan Diego, CA

Wenzhong Guo
CTO, Cell Therapy at Sorrento Therapeutics, USA

Profile

Dr. Guo is the CTO of Cell Therapy in Sorrento Therapeutics Inc and has ~30 years of research and product development experience in Tumor Immunology, antibody drug development and T/NK cell Therapy. He is leading non-viral vector CAR/DAR-T cell therapy product development including R&D, process development and manufacturing in Sorrento. Dr. Guo obtained his Ph.D. in Tumor Immunology from State Key lab of Molecular Oncology of Chinese Academy of Medical Sciences and did tumor immunology research in M.D. Anderson Cancer Center in Houston and National Jewish Health in Denver. He has over 10 years- experience in cell therapy industry.

Agenda Sessions

  • Non-Viral Vector Engineered Allogeneic T Cell Therapies Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

    1:30pm